Mabwell
Innovative Biopharmaceutical Company
UniXell
Cell Therapy Drug Developer
Recently, enterprises in Zhangjiang Pharma Valley have continuously enhanced their product competitiveness and overseas channel layout capabilities, successively gaining recognition from domestic and international institutions.
Toumai® Robot Global Commercial Orders Exceed 300 Units
June 16,Zhangjiang Pharma Valley Enterprise MicroPort® RoboticsAnnounced that the company’s independently developed Toumai® robotic system has officially surpassed 300 global commercial orders, making it one of the top two laparoscopic surgical robots worldwide to achieve large-scale international commercial deployment. Notably, new orders received in the first half of 2026 have already exceeded the total for the entire previous year, significantly leading the global commercialization progress of Chinese-made surgical robots.
Toumai® Robot Continues to Break Through in the Southeast Asian Market
(Image source: MicroPort)
Toumai® has obtained market access in over 100 countries and regions, covering major medical markets in Asia, Europe, Latin America, Oceania, and Africa, thereby establishing a comprehensive global market access framework.
To meet the rapidly growing market demand for various surgical robots, MicroPort® Robot has established a comprehensive, multi-tiered supply chain system covering precision components, specialized consumables, core assemblies, and system integration, thereby forming robust capabilities in research and development, manufacturing, and delivery.
Currently, multiple marketed robotic products, including the Toumai® robot, along with their associated consumables, have achieved large-scale production, with an overall annual capacity reaching 500 units. This provides a solid foundation for global commercial expansion and growth in installations.
Mabwell’s Nectin-4-Targeting ADC 9MW2821: Two Clinical Achievements Presented at the 2026 ESMO Gynaecological Oncology Annual Meeting
Today,Mabwell, a Zhangjiang Pharma Valley EnterpriseAnnouncement: Two latest clinical findings of the company’s independently developed Nectin-4-targeting ADC 9MW2821 (Bulumtatug Fuvedotin, BFv) for the treatment of cervical cancer were presented at the ESMO Gynaecological Cancers Congress 2026 (ESMO Gynae 2026), held in Copenhagen, Denmark, from June 17 to 19. The results of both studies demonstrated that 9MW2821 exhibited a manageable safety profile and positive therapeutic efficacy in patients with cervical cancer, with a trend toward ultra-long survival benefits observed particularly in patients previously treated with immunotherapy. Furthermore, its combination with PD-1 inhibitors showed remarkable antitumor activity in the treatment of advanced cervical cancer.
Professor Yang Huijuan, Fudan University Shanghai Cancer CenterDeliver an In-Depth Report on Behalf of the Research Team
(Image source: Mabwell)
9MW2821 is an innovative Nectin-4-targeting antibody-drug conjugate (ADC) independently developed by Mabwell based on its ADC development platform. The company has established a comprehensive pipeline combining ADCs with immunotherapy. 9MW2821 is the first Nectin-4 ADC globally to enter Phase III clinical trials for the indications of cervical cancer (CC) and triple-negative breast cancer (TNBC). Four pivotal Phase III registrational clinical trials have been initiated for this candidate. Three indications have received Fast Track Designation from the U.S. Food and Drug Administration (FDA), one indication has been granted Orphan Drug Designation, and two indications have been included in the Breakthrough Therapy Designation list by the Center for Drug Evaluation (CDE).
UniXell's UX-DA003 Receives FDA Clearance for Clinical Trials
June 19,UniXell Biotechnology, Zhangjiang Pharma ValleyAnnouncement: UX-DA003 (Allogeneic iPSC-Derived Midbrain Dopaminergic Neural Progenitor Cell Injection) Receives FDA Implicit Approval for Clinical Trials. This marks another key milestone in UniXell’s internationalization journey, following the product’s receipt of implicit approval for clinical trials from the NMPA on June 3, 2026.
(Image source: UniXell)
With the FDA approval of UX-DA003, UniXell has become one of the few companies worldwide to master both autologous and allogeneic iPSC cell therapy technologies for Parkinson’s disease, establishing a differentiated product portfolio tailored to distinct patient populations:
Autologous Pathway (UX-DA001):Prepared using the patient’s own cells, it completely avoids the risk of immune rejection. Currently, the product is undergoing Phase I clinical trials at Shanghai Ruijin Hospital. The first treated patient has completed one year of follow-up, with clinical data demonstrating a favorable safety profile and significant efficacy; the patient has regained the ability to live independently. In June 2025, the product was granted Fast Track Designation by the U.S. FDA.
Allogeneic Pathway (UX-DA003):Leveraging a universal iPSC seed cell bank enables scalable production. Preclinical studies have demonstrated that UX-DA003 significantly ameliorates motor deficits in animal models of Parkinson’s disease and precisely integrates into host brain circuits to form functional connections, offering new hope for patients with urgent therapeutic needs.
Mabwell’s Dual-Target siRNA Enters Phase I Clinical Trials in Australia
Recently,Mingwei Biologics, a Zhangjiang Pharma Valley EnterpriseThe independently developed innovative dual-target small interfering RNA (siRNA) drug, MWX205 injection, has officially submitted its Phase I clinical trial application to the Australian Human Research Ethics Committee (HREC) and received approval.
(Image source: Minwei Biologics)
This project aims to provide a more potent and longer-lasting lipid-lowering solution for patients with hyperlipidemia and atherosclerotic cardiovascular disease (ASCVD) by simultaneously inhibiting two key targets, PCSK9 and ANGPTL3. As the first PCSK9/ANGPTL3 dual-target siRNA globally to enter clinical development, it marks Shanghai Minwei Biotechnology’s entry into the stage of dual-target siRNA therapy in the fields of metabolic and cardiovascular diseases.
Compiled from: Pharmaceutical Notes, Official Corporate WeChat Accounts